ReviewClinical & developmental immunology2011
Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?
Review in Clinical & developmental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Immunomodulatory Properties of Natural Extracts and Compounds Derived fromPharmaceutics · 2023Review
- Eulogy for the Metabolic Clinical Investigator?Diabetes · 2016Article
- Experimental Diabetes Mellitus in Different Animal Models.Journal of diabetes research · 2016Review
- Gut immune deficits in LEW.1AR1-iddm rats partially overcome by feeding a diabetes-protective diet.Immunology · 2015Article
- Induction of Tolerogenic Dendritic Cells by a PEGylated TLR7 Ligand for Treatment of Type 1 Diabetes.PloS one · 2015Article
- Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes.Journal of diabetes science and technology · 2014Review
- Immunotherapeutic strategies in autoimmune uveitis.Autoimmunity reviews · 2014Review
- Review
- Novel autoantigens in type 1 diabetes.American journal of translational research · 2013Article
- Role of immune system modulation in prevention of type 1 diabetes mellitus.Indian journal of endocrinology and metabolism · 2012Article
- Expanding the clinical indications for α(1)-antitrypsin therapy.Molecular medicine (Cambridge, Mass.) · 2012Review
- Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.Immunological reviews · 2012Review
- Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Peripheral blood monocyte gene expression profile clinically stratifies patients with recent-onset type 1 diabetes.Diabetes · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thus far, none of the preclinically successful and promising immunomodulatory agents for type 1 diabetes mellitus (T1DM) has conferred stable, long-term insulin independence to diabetic patients. The majority of these immunomodulators are humanised antibodies that target immune cells or cytokines. These as well as fusion proteins and inhibitor proteins all share varying adverse event occurrence and severity. Other approaches have included intact putative autoantigens or autoantigen peptides. Considerable logistical outlays have been deployed to develop and to translate humanised antibodies targeting immune cells, cytokines, and cytokine receptors to the clinic. Very recent phase III trials with the leading agent, a humanised anti-CD3 antibody, call into question whether further development of these biologics represents a step forward or more of the same. Combination therapies of one or more of these humanised antibodies are also being considered, and they face identical, if not more serious, impediments and safety issues. This paper will highlight the preclinical successes and the excitement generated by phase II trials while offering alternative possibilities and new translational avenues that can be explored given the very recent disappointment in leading agents in more advanced clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.